Skip to main content

Table 5 Multivariate analysis

From: Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT

 

Relapse

NRM

Acute GVHD

Chronic GVHD

LFS

OS

 

p value

HR (95 % CI)

p value

HR (95 % CI)

p value

OR (95 % CI)

p value

HR (95 % CI)

p value

HR (95 % CI)

p value

HR (95 % CI)

RIC vs. MAC

 All

0.07

1.31 (0.98–1.75)

0.76

0.95 (0.69–1.31)

0.32

0.82 (0.55–1.21)

0.21

0.80 (0.56–1.14)

0.27

1.13 (0.91–1.40)

0.44

1.09 (0.87–1.36)

 AML

0.09

1.34 (0.95–1.87)

0.17

0.78 (0.54–1.12)

    

0.74

1.04 (0.81–1.34)

0.79

0.97 (0.75–1.25)

 ALL

0.5

1.23 (0.67–2.26)

0.18

1.5 (0.83–2.72)

    

0.17

1.34 (0.88–2.05)

0.10

1.44 (0.94–2.22)

Age at SCT

 1. <30 (ref)

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 2. (30–40) vs. 1

0.91

1.02 (0.68–1.54)

0.27

0.79 (0.51–1.20)

0.98

1.01 (0.60–1.70)

0.25

0.75 (0.46–1.22)

0.47

0.90 (0.67–1.20)

0.52

0.91 (0.67–1.23)

 3. (40–50) vs. 2

0.43

0.84 (0.55–1.28)

0.74

1.08 (0.69–1.69)

0.98

1.01 (0.58–1.77)

0.70

0.91 (0.56–1.48)

0.74

0.95 (0.70–1.29)

0.79

0.96 (0.69–1.32)

 4. ≥ 50 vs. 3

0.11

1.33 (0.93–1.90)

0.48

0.87 (0.59–1.28)

0.06

1.62 (0.98–2.70)

0.44

1.18 (0.77–1.79)

0.52

1.09 (0.84–1.42)

0.79

1.04 (0.79–1.36)

ALL vs. AML

0.04

1.39 (1.02–1.91)

0.37

1.16 (0.84–1.61)

0.65

1.10 (0.73–1.66)

0.50

1.13 (0.79–1.63)

0.03

1.28 (1.02–1.61)

0.03

1.30 (1.03–1.64)

Status at SCT

 CR1 (ref)

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

  ≥ CR2 vs. CR1

0.05

1.46 (1.01–2.13)

0.45

1.15 (0.80–1.63)

0.35

1.24 (0.80–1.92)

0.23

1.25 (0.87–1.78)

0.05

1.30 (1.00–1.67)

0.01

1.40 (1.07–1.83)

 Active dis. vs. CR1

<10–4

4.43 (3.20–6.12)

0.0002

1.86 (1.34–2.59)

0.85

1.04 (0.68–1.60)

0.45

1.17 (0.78–1.75)

<10–4

2.94 (2.34–3.70)

<10–4

2.92 (2.30–3.72)

PB vs. BM

0.85

1.03 (0.77–1.37)

0.59

1.09 (0.80–1.48)

0.0008

1.96 (1.32–2.92)

0.005

1.64 (1.16–2.30)

0.63

1.05 (0.85–1.30)

0.58

1.06 (0.85–1.32)

PT-Cy-based vs. other

0.94

0.99 (0.72–1.36)

0.02

0.63 (0.44–0.92)

0.11

0.69 (0.44–1.09)

0.46

1.15 (0.79–1.69)

0.10

0.82 (0.64–1.04)

0.16

0.83 (0.65–1.07)

Year of SCT

 2001–2005 (ref)

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 

1.00

 2005–2007

0.86

1.08 (0.48–2.43)

0.74

0.89 (0.45–1.77)

0.62

1.24 (0.44–3.51)

0.17

2.03 (0.74–5.56)

0.89

0.96 (0.57–1.63)

0.84

1.06 (0.61–1.83)

 2008–2012

0.98

0.99 (0.47–2.09)

0.22

0.68 (0.36–1.27)

0.27

1.68 (0.67–4.22)

0.14

2.04 (0.80–5.19)

0.40

0.81 (0.50–1.31)

0.60

0.87 (0.53–1.44)

  1. Active dis active disease, BM bone marrow, PT-Cy-based post-transplant cyclophosphamide associated to one calcineurin inhibitor and mycophenolate mofetyl, CR complete remission, GVHD graft-versus-host-disease, LFS leukemia-free survival, NRM non-relapse mortality, MAC myeloablative conditioning, OS overall survival, PB peripheral blood, Ref reference, RIC reduced intensity conditioning, SCT allogeneic stem cell transplantation
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us